Theralymph : An innovative therapy for lymphedema
OUR MAIN OBJECTIVES
Describe the physiopathology of lymphedema to better understand mechanisms of loss of lymphatic function.
Identify therapeutic targets for lymphedema to restore the lymphatic flow.
Validate therapeutic targets in preclinic models of lymphedema.
Perform a Phase I/IIa gene therapy clinical trial on patients who developed lymphedema after breast cancer using lentiflash vectors.
Post-doctoral position at I2MC-Toulouse (France) : Theralymph : An innovative therapy for lymphedema A postdoctoral position, with salary funded for three years is available in the team “Molecular regulations of (lymph)angiogenic growth factors in vascular diseases”...
Current vacancies: The Institute of Metabolic and Cardiovascular Diseases (I2MC) in Toulouse is looking for a highly motivated post-doctoral fellow for the 3-years Theralymph Horizon 2020 project to perform an innovative gene therapy for lymphedema. The selected...
The project has been officially launched on January 1st 2020.